Solvuu retweeted
The Reference Material Forum at AMP 2026 is one month away. Solvuu's CSO @raj_sasidharan7 will present "Truth-Defined, Assay-Matched In Silico Reference Materials for Hard-to-Source Variant Classes." See you in Seattle!
amp2026.eventscribe.net/agen…
Solvuu retweeted
"While clinical validation and use of NGS in many settings is established, there are continuing challenges as technologies and the associated informatics evolve."
That was Rehder et al. in ACMG's 2021 technical standard on NGS. Do you work in a genetics lab? What challenges do you still face in bringing your tests to market, from development and validation to regulatory review and commercial deployment?
nature.com/articles/s41436-0…
Solvuu retweeted
Molecular diagnostic laboratories may have 1 to 2 bioinformaticians or teams of 10 to 20 or more. @sabahkadri, @asbonerw, and colleagues (J Mol Diagn. 2025) wrote that pipeline design depends on assay, technology, and specimen type, and that bioinformaticians are included in the build-versus-buy decision. They present an initial framework. A single person will not have the full list of skills. Webinar on Sep 23rd.
jmdjournal.org/article/S1525…
Solvuu retweeted
AMP’s Molecular Diagnostics Core puts bioinformaticians in all four phases of test development: familiarization; design, development, and optimization; analytical validation; and the quality-management system.
Leon et al. (J Mol Diagn. 2025) present an initial framework, not a standard of practice.
jmdjournal.org/article/S1525…
Solvuu retweeted
AMP defined a clinical bioinformatician as someone who develops, validates, and deploys pipelines in a regulated clinical laboratory, not a research setting.
@roysomak4 and colleagues (J Mol Diagn. 2025) wrote that definition as three knowledge cores and an initial framework. A single person will not have all of the skills.
jmdjournal.org/article/S1525…
Solvuu retweeted
The AMP 2026 Reference Material Forum program is now posted. This November will be our fourth AMP, and the first time @solvuu is presenting.
@raj_sasidharan7, our CSO, is speaking. I will be there too!
See the program here:
amp2026.eventscribe.net/agen…
Solvuu retweeted
Publicly available physical reference materials cover only 29.4% of variants on two expert-curated germline lists. @roysomak4 et al. write that in silico mutagenized files can be a valuable supplement to physical samples.
jmdjournal.org/article/S1525…
Solvuu retweeted
Meet @solvuu at the @elabNYC Life Science Masterclass by @FirstXFounder!
Ashish Agarwal (@agarwal1975), Solvuu's Founder, is joining a panel discussion on leveraging a commercial plan for attracting partners and investors.
To learn more👇
linkedin.com/posts/solvuu_ne…
Solvuu retweeted
Attending @BioTechX_ this year? Join us for a panel discussion and connect with @rtasakis to explore how @solvuu can help accelerate your bioinformatics/healthcare data analytics goals for therapeutics and diagnostics!
#biotechx #biotechx2024 #solvuu
linkedin.com/feed/update/urn…
Solvuu retweeted
𝗥𝗲𝘁𝗵𝗶𝗻𝗸𝗶𝗻𝗴 𝗠𝗗𝗦 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀: 𝗡𝗚𝗦-𝗱𝗿𝗶𝘃𝗲𝗻 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗶𝗻 𝗣𝗲𝗿𝗶𝗽𝗵𝗲𝗿𝗮𝗹 𝗕𝗹𝗼𝗼𝗱 𝗮𝘀 𝗮 𝗟𝗲𝘀𝘀 𝗜𝗻𝘃𝗮𝘀𝗶𝘃𝗲 𝗔𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲 𝘁𝗼 𝗕𝗼𝗻𝗲 𝗠𝗮𝗿𝗿𝗼𝘄 𝗕𝗶𝗼𝗽𝘀𝘆
To learn more👇
hubs.ly/Q02Bx9wh0
Solvuu retweeted
Optical Genome Mapping (OGM) is a non-sequencing technology, which possesses the capability to analyze extensive eukaryotic genomes and their structural attributes with remarkable precision.
Learn more about OGM and its applications in the link below.👇
hubs.ly/Q02xfYyJ0
Solvuu retweeted
𝙒𝙝𝙖𝙩 𝙥𝙚𝙧𝙩𝙪𝙧𝙗𝙖𝙩𝙞𝙤𝙣 𝙙𝙖𝙩𝙖𝙨𝙚𝙩𝙨 𝙘𝙖𝙣 𝙖𝙨𝙨𝙞𝙨𝙩 𝙞𝙣 𝙪𝙣𝙙𝙚𝙧𝙨𝙩𝙖𝙣𝙙𝙞𝙣𝙜 𝙝𝙪𝙢𝙖𝙣 𝙙𝙞𝙨𝙚𝙖𝙨𝙚 𝙖𝙣𝙙 𝙞𝙙𝙚𝙣𝙩𝙞𝙛𝙮𝙞𝙣𝙜 𝙣𝙤𝙫𝙚𝙡 𝙩𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨?
Follow the link to learn more👇
hubs.ly/Q02spnJj0
Solvuu retweeted
𝙒𝙝𝙖𝙩 𝙘𝙮𝙗𝙚𝙧𝙨𝙚𝙘𝙪𝙧𝙞𝙩𝙮 𝙥𝙧𝙤𝙩𝙤𝙘𝙤𝙡𝙨 𝙢𝙪𝙨𝙩 𝙗𝙚 𝙞𝙢𝙥𝙡𝙚𝙢𝙚𝙣𝙩𝙚𝙙 𝙩𝙤 𝙚𝙛𝙛𝙚𝙘𝙩𝙞𝙫𝙚𝙡𝙮 𝙢𝙖𝙣𝙖𝙜𝙚 𝙖𝙣𝙙 𝙨𝙖𝙛𝙚𝙜𝙪𝙖𝙧𝙙 𝙜𝙚𝙣𝙤𝙢𝙞𝙘 𝙙𝙖𝙩𝙖 𝙨𝙩𝙤𝙧𝙖𝙜𝙚?
To learn more👇
hubs.ly/Q02phHxF0
Solvuu retweeted
The human pangenome enables more precise analysis of clinically relevant genetic variation. This is a major step forward in our understanding of human genetics, offering a comprehensive view of genetic variation across diverse populations. To learn more👇
hubs.ly/Q02l24Mr0
Solvuu retweeted
𝗪𝗵𝗮𝘁 𝗶𝘀 𝘁𝗵𝗲 𝙞𝙣 𝙫𝙞𝙫𝙤 𝗳𝗮𝘁𝗲 𝗼𝗳 𝗖𝗔𝗥-𝗧 𝗰𝗲𝗹𝗹𝘀 𝗮𝗳𝘁𝗲𝗿 𝗶𝗻𝗳𝘂𝘀𝗶𝗼𝗻?
Click the link to learn more👇
hubs.ly/Q02jkJlg0
Solvuu retweeted
ELVAR is a novel approach to single-cell RNA-seq analysis, which employs cell-attribute-aware clustering and enables accurate detection of cell-type composition changes. @AMaity5485 developed ELVAR prior to joining us. To learn more, click the link👇
linkedin.com/posts/solvuu_ce…
Solvuu retweeted
We are hiring a bioinformatics engineer @solvuu! Please apply for our new job opening if you want to join a great team and work on a range of impactful scientific projects. #Bioinformatics #Genomics #AWS #Job
linkedin.com/jobs/view/87449…
Solvuu retweeted
Currently at Biolabs@NYULangone: resident companies @solvuu @RedesignScience Deck Therapeutics and C2i Genomics chat with managing director Nishta Rao about our space (and what they’re doing in it). Another great @LaunchBio event!
Solvuu retweeted
Join us in our space this Wednesday!!
"LARGER THAN LIFE SCIENCE | Trust Your Gut"
Register here: launchbio.org/location/nyc
Solvuu retweeted
What better way to end the day than drinking in the wisdom of decades of #biotech #entrepreneurship? Fireside chat with Robert Schneider of @nyulangone @BioLabsNY and our own @labknight at #Foundation2019. @echo_nyc







